昂利康：获得左氧氟沙星片药品注册证书

Core Viewpoint - The company has received a drug registration certificate for Levofloxacin Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Product Information - Levofloxacin Tablets are classified as a third-generation fluoroquinolone antibiotic, known for their broad antibacterial spectrum and strong antibacterial action [1] - The drug is intended for the treatment of mild, moderate, and severe infections in adults (≥18 years) caused by specified sensitive strains [1] Group 2: Regulatory Milestones - The company received the notice of acceptance for the drug's marketing authorization application in April 2024, followed by the recent approval [1]